What is the mechanism of action of Tucatinib? How to target HER2-positive cancers?

Tucatinib (also known as tucatinib) is an oral small molecule tyrosine kinase inhibitor that specifically targets human epidermal growth factor receptor 2 type (HER2). HER2 is a receptor protein located on the cell surface, involved in regulating cell growth and division. When the HER2 gene is overexpressed or amplified, it can lead to abnormal cell proliferation, leading to a variety of cancers, especially breast cancer, gastric cancer, and some colorectal cancers. Tucatinib inhibits the growth of tumor cells by interfering with the HER2 signaling pathway.

Unlike other HER2 inhibitors, tucatinib is highly selective for HER2 and has almost no inhibitory effect on HER1 (EGFR). This selectivity reduces side effects caused by EGFR inhibition, such as diarrhea and rash, making it more clinically tolerable. This feature allows tucatinib to be used more safely in combination with other anti-HER2 drugs (such as trastuzumab, capecitabine, etc.) to enhance the therapeutic effect, especially for patients with HER2-positive advanced breast cancer who are resistant to multi-line therapy.

In HER2 positive cancers, the mechanism of action of tucatinib is to block the activity of HER2 kinase and prevent the activation of its downstream signaling pathways (such as PI3K/AKT and MAPK pathways). These signaling pathways are usually responsible for promoting cell growth and inhibiting apoptosis. The intervention of tucatinib can induce cancer cell death or stop dividing, achieving the purpose of controlling tumor progression. Especially in patients with brain metastases, tucatinib shows good penetration into the central nervous system and can control intracranial lesions, which is a major advantage.

In general, tucatinib, as a new, highly selective HER2 targeted drug, provides a new treatment option for HER2 positive cancers, especially patients with advanced breast cancer. Its synergistic effect with other anti-HER2 drugs has been verified in multiple clinical trials and is expected to play an important role in the treatment of more HER2-related cancers in the future. Patients should do this before using this medicineHER2 status testing, and individualized treatment plans formulated under the guidance of professional doctors.

Reference materials:https://www.tukysa.com/